N. S. Prizova

First-line immunotherapy for patients with metastatic non-small cell lung cancer not eligible for a platinum-based chemotherapy

Immune checkpoint inhibitors alone or in combination with platinum-based doublet chemotherapy is the standard first-line treatment for patients with metastatic non-small cell lung cancer (mNSCLC) without driver mutations. It should be recognized, however, that treating patients who are not eligible for platinum-based c...